This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on Web of Science (5)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

M. ALLEN FORBES, Jr., M.D.; Hazel G. Cook, M.T. (A. S. C. P.), B.A.

AMA Arch Derm Syphilol. 1953;68(6):631-634.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

DURING the time that has elapsed since Waksman¹ and his co-workers discovered neomycin, it has become one of the accepted antibiotics for the treatment of cutaneous bacterial infections. Numerous investigators² have reported that this antibiotic is a very valuable therapeutic agent for the topical treatment of bacterial infections of the skin when applied either as an ointment or in aqueous solution. The work of Livingood³ and his co-workers indicates that it is particularly effective for staphylococcic infections and that its spectrum includes a fair percentage of most of the bacteria which are of importance in the etiology of cutaneous bacterial infections.

Perhaps it is appropriate to state that there is no one antibiotic⁴ for topical treatment of skin infections that is distinctly superior to all others. For example, it is generally agreed that both oxytetracycline (Terramycin) and chlortetracycline (aureomycin) are superior to neomycin in . . . [Full Text PDF of this Article]

Author Affiliations
AUSTIN, TEXAS

From the Department of Dermatology and Syphilology, University of Texas School of Medicine (Clarence S. Livingood, M.D., Director) and the University of Texas Health Center (Dr. Forbes), and the University of Texas Department of Bacteriology (Hazel Cook).

Footnotes
The neomycin used in this study was supplied by The Upjohn Company, Kalamazoo, Mich.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?